Pharmaceutical firms' lower-than-historical valuations and high-margin, patent-protected products are positive signs for investors seeking more yield.
Slowing demand has pushed gold prices down during the past year, but good exposure to the commodity can be had through several growth-oriented names.
The market is undervaluing how the boost in new customers will offset new regulations for managed-care companies, says Morningstar's Matt Coffina.
Despite a mixed bag in the tech giant's fiscal first quarter, the firm's growing earnings power makes Apple shares attractive, says Morningstar's Brian Colello.
Cara Esser explains the fundamentals behind Morningstar's CEF Analyst Ratings and what investors should keep in mind before buying or selling a fund.
With the U.S. market for life insurance mature, firms are increasingly looking to Asia for growth, says Morningstar's Drew Woodbury.
Covered-call strategies in CEFs allow for higher distribution rates, but Morningstar's Cara Esser says investors should look for the underlying strategy first and not just the covered-call strategy.
These three exemplary managers have widened their firms' economic moats and created real value for shareholders over the years.
A 36-year-old IT executive crafts a plan for fulfilling his financial ambitions.
Dec. 6-10, 2010.
While Warren Buffett may have put the kibosh on a dividend for Berkshire's shareholders, he and the rest of our Ultimate Stock-Pickers continue to hold stocks yielding more than the S&P 500 Index.
©2012 Morningstar Advisor. All right reserved.